Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sangamo Therapeutics, Inc. (SGMO) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI‑generated summaries that help explain their contents. Sangamo is a genomic medicine company listed on the Nasdaq Capital Market, and its filings document clinical, regulatory, financial and listing‑related developments across its Fabry disease and neurology‑focused pipeline.
Investors can review Sangamo’s current reports on Form 8‑K, which the company uses to report material events. Recent 8‑Ks describe positive topline and updated data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST‑920) in Fabry disease, including mean annualized estimated glomerular filtration rate (eGFR) slopes and safety findings, as well as the FDA’s agreement to use eGFR slope as an endpoint for an accelerated approval pathway. Other 8‑Ks cover quarterly financial results, collaboration and license agreements, executive transitions and a Nasdaq notice granting additional time to regain compliance with the minimum bid price requirement.
Annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) provide more detailed information on Sangamo’s research and development expenses, general and administrative costs, cash and cash equivalents, and risk factors related to its genomic medicine programs, collaborations and capital needs. These filings also elaborate on the company’s description of its business as a neurology‑focused genomic medicine company and its reliance on investigational product candidates such as ST‑920, ST‑503 and ST‑506.
On this page, Stock Titan’s tools surface new SGMO filings from EDGAR in near real time and apply AI‑powered analysis to highlight key points, such as clinical endpoints referenced in 8‑Ks, updates on BLA preparation activities, or disclosures about Nasdaq listing compliance. Users can also locate proxy statements and other governance‑related documents to better understand Sangamo’s executive compensation plans and board‑level decisions, as referenced in its SEC filings. This combination of source documents and AI summaries is intended to make it easier to interpret complex regulatory language without replacing the need to read the original filings.
Sangamo Therapeutics (SGMO) reported an insider transaction on Form 4. The company’s SVP, Chief Legal Officer and Secretary executed a tax-withholding disposition tied to RSU vesting on 10/22/2025. 44,122 shares of common stock were withheld (code F) at $0.66 per share using the issuer’s closing price. Following the transaction, the reporting person beneficially owns 704,121 shares, held directly.
The filing notes these shares were surrendered solely to cover taxes upon vesting under the Amended and Restated 2018 Equity Incentive Plan and do not reflect an open-market sale. It also outlines remaining RSU vesting schedules, including portions from grants dated 1/22/2024, 2/24/2023, and 2/25/2025, subject to continuous service and plan terms.
Sangamo Therapeutics (SGMO) insider filing: the President, CEO and Director reported an automatic share withholding tied to RSU vesting. On October 22, 2025, 126,950 shares were withheld for mandatory taxes at a price of $0.66 per share, following the vesting of a portion of a restricted stock unit grant. After these transactions, the reporting person beneficially owned 2,057,022 shares, held directly.
The filing notes RSU schedules: 123,050 shares resulted from the October 22, 2025 vesting installment of a January 22, 2024 grant, with the remaining 250,000 shares vesting in equal quarterly installments through January 22, 2026. It also includes 29,494 shares from a February 24, 2023 grant vesting in equal quarterly installments through February 24, 2026, and 375,000 shares from a February 25, 2025 grant vesting one-fourth on February 25, 2026, with the balance in eight successive equal quarterly installments thereafter. All vesting is subject to continuous service and the plan’s terms.
Sangamo Therapeutics (SGMO) officer files Form 4 disclosing a tax-withholding transaction tied to RSU vesting. On 10/22/2025, the Principal Financial Officer surrendered 45,225 shares at $0.66 per share under transaction code F, which reflects shares withheld for taxes, not an open‑market sale.
Following the transaction, the officer beneficially owned 699,262 shares. The filing notes RSU activity and schedules: 43,837 shares vested on 10/22/2025 from a 1/22/2024 grant, with 89,063 shares scheduled to vest in equal quarterly installments through 1/22/2026; 10,020 shares from a 2/24/2023 grant vest in equal quarterly installments through 2/24/2026; and 120,000 shares from a 2/25/2025 grant vest 1/4 on 2/25/2026 and the balance in eight successive equal quarterly installments thereafter, subject to continuous service and potential acceleration under the company’s 2018 Equity Incentive Plan.
Sangamo Therapeutics (SGMO): A company officer reported an administrative share withholding tied to RSU vesting. On October 22, 2025, 6,708 shares were surrendered to the issuer solely for mandatory tax withholding at $0.66 per share. This was not an open‑market trade.
Following the transaction, the officer reports 246,295 shares beneficially owned. The filing notes ongoing RSU schedules, including shares from the January 22, 2024, February 24, 2023, and February 25, 2025 grants with vesting through 2026, conditioned on continuous service.
Sangamo Therapeutics (SGMO) reported an insider tax-withholding transaction tied to RSU vesting. On 10/22/2025, the Head of Research & Technology surrendered 6,708 shares at $0.66 per share for mandatory tax withholding, a disposition to the issuer that is not an open‑market trade.
Following the transaction, the insider beneficially owned 194,514 shares. The RSU details note 12,042 shares vested on 10/22/2025, with remaining tranches of 18,750, 4,043, and 49,726 shares scheduled to vest per grant terms, subject to continuous service and potential acceleration under the 2018 EIP.
Sangamo Therapeutics (SGMO) director and Principal Accounting Officer Nikunj Jain reported initial beneficial ownership on
Sangamo Therapeutics disclosed that its Chief Financial Officer, Prathyusha Duraibabu, resigned effective October 1, 2025 and will transition to part-time employment to continue as the company’s principal financial officer. The Board appointed Nikunj Jain, Vice President, Finance and Corporate Controller since September 2021, to serve as Sangamo’s principal accounting officer effective October 1, 2025. Mr. Jain’s employment agreement provides a $347,548 annual base salary and a target annual cash bonus equal to 30% of base salary; he remains eligible for annual equity awards and severance benefits under the company plans. Ms. Duraibabu’s amended agreement is expected to provide a $145,188 base salary and a $160,000 cash retention bonus payable January 31, 2026, subject to continued employment.
Sangamo Therapeutics reported that its Chief Financial Officer, Prathyusha Duraibabu, notified the company on September 9, 2025 that she will resign effective October 1, 2025 to join a privately-held artificial intelligence company. The filing states her departure is not due to any disagreement over the company’s operations, financial statements, internal controls, auditors, policies, or practices. For business continuity, Ms. Duraibabu will move to part-time employment on the Transition Date and will continue to serve as the company’s principal financial officer and principal accounting officer on an interim basis until a successor is appointed. The company acknowledged her contributions, including work on strategic collaborations and investment allocations as Sangamo focuses on becoming a neurology-focused genomic medicines company.
Sangamo Therapeutics (SGMO) presented updated registrational Phase 1/2 STAAR study data for isaralgagene civaparvovec (ST-920) for Fabry disease at ICIEM2025. As of the April 10, 2025 cutoff, 33 patients (age 18–67) were dosed with a median follow-up of 24 months and all 32 remaining patients had achieved at least 52 weeks of follow-up. The FDA agreed that STAAR data will serve as the primary basis for Accelerated Approval using the 52-week eGFR slope across patients as an intermediate clinical endpoint. Observed mean annualized eGFR slopes at 52 weeks were positive: 1.965 mL/min/1.73m2/year (95% CI: -0.153, 4.083) and RIRS estimate 2.020 (95% CI: -0.055, 4.095). Sangamo is preparing a BLA under Accelerated Approval with potential submission as early as Q1 2026, subject to securing additional funding.
Sangamo Therapeutics (SGMO) director and President & CEO Sandy Macrae reported a Form 4 disclosing a tax-withholding disposition tied to RSU vesting. On 08/24/2025, 7,488 shares were surrendered for mandatory tax withholding at the issuer's closing price of $0.5863 per share. The filing reports 2,183,972 shares beneficially owned following the transaction. The disposition reflects vested restricted stock units from prior grants and is described as a required withholding action under the company’s 2018 Equity Incentive Plan rather than an open-market sale. The filing details remaining scheduled vesting for multiple RSU grants, with specific vesting installments through February 2026 and January 2026 and contingent on continuous service.
FAQ
What is the current stock price of Sangamo Therapeutics (SGMO)?
What is the market cap of Sangamo Therapeutics (SGMO)?
